{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-160769","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.492814+00:00","generated_at":"2026-06-01T04:40:42.651866+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Sensei Biotherapeutics stockholders reelect all three director nominees at 2024 annual meeting","bullets":["Elected directors Jessie English, James Peyer, Thomas Ricks; each received ~9-10M votes for, ~0.8-1.9M withheld.","Ratified Deloitte & Touche as independent auditor for FY 2024 with 16.3M for, 0.8M against, 17k abstentions.","Approximately 68.2% of outstanding shares (17.1M of 25.1M) were present or represented at the meeting.","Broker non-votes on director election totaled ~6.1M for each nominee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-160769","json":"https://secwatch.observer/filing/0001193125-24-160769.json","markdown":"https://secwatch.observer/filing/0001193125-24-160769.md","text":"https://secwatch.observer/filing/0001193125-24-160769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524160769/0001193125-24-160769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524160769/d806149d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:40:42.651866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}